SCHEDULE: Akari Therapeutics Insider Discloses 18.4% Stake

Dr. Hoyoung Huh has reported beneficial ownership of 18.4% of Akari Therapeutics Plc's ordinary shares, including options and warrants.

Summary

• Hoyoung Huh, M.D., Ph.D., beneficially owns 18,199,697,667 ordinary shares of Akari Therapeutics Plc.
• This represents 18.4% of the company's ordinary shares outstanding as of March 1, 2026.
• The total outstanding ordinary shares used for calculation were 91,567,009,533 as of March 1, 2026.
• The beneficial ownership comprises 9,391,708,000 shares held directly, 1,061,691,667 shares underlying options exercisable within 60 days, 103,482,000 shares underlying warrants exercisable within 60 days, 7,423,902,000 shares underlying prefunded warrants exercisable within 60 days, and 218,914,000 shares held by Hannol Ventures LLC.
• Excluded from this beneficial ownership are up to 10,995,330,000 shares underlying warrants subject to a 9.99% beneficial ownership limitation, where beneficial ownership is disclaimed if exercise would exceed this percentage.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive disclosure, as a substantial insider stake by Dr. Hoyoung Huh suggests strong alignment of interests with shareholders and potential confidence in Akari Therapeutics' future prospects.

Positives

• A significant insider stake of 18.4% by Dr. Hoyoung Huh, potentially indicating strong confidence in the company's future prospects and alignment with shareholder interests.
• The beneficial ownership includes a substantial number of shares underlying options and warrants exercisable within 60 days, which could represent future capital inflow to the company upon exercise.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that significant insider ownership, such as the 18.4% stake disclosed by Dr. Hoyoung Huh, can often be interpreted by the market as a sign of strong conviction from key personnel, potentially differentiating Akari Therapeutics from peers with lower insider alignment.

Comparison to Industry Standards

• Insider ownership levels vary widely across industries and company stages. For a biotechnology company like Akari Therapeutics, an 18.4% beneficial ownership by a key individual like Dr. Huh is a substantial stake, often exceeding average insider holdings seen in larger, more mature pharmaceutical companies where institutional ownership typically dominates. This level of insider commitment is more common in smaller, development-stage biotechs, where founders and early investors retain significant control and exposure.

Related Party Transactions

• The beneficial ownership includes 218,914,000 shares held of record by Hannol Ventures LLC, which is included in the reporting person's aggregate beneficial ownership, suggesting a related party relationship or control.

Stakeholder Impact

• Shareholders may view the significant insider ownership as a positive signal of management's commitment and belief in the company's long-term value.
• The inclusion of shares underlying options and warrants indicates potential future dilution if exercised, but also potential capital inflow to the company.

Key Dates

Recommendation

While the significant insider ownership by Dr. Hoyoung Huh is a positive indicator of confidence and alignment, a Schedule 13G filing alone does not provide sufficient operational or financial details to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and seek further information on the company's financial performance, strategic developments, and pipeline progress to make a more informed investment decision.

Keywords

Akari Therapeutics, Hoyoung Huh, beneficial ownership, Schedule 13G, insider ownership, ordinary shares, ADSs, warrants, options, prefunded warrants